- £68.12bn
- £80.41bn
- £30.33bn
- 87
- 46
- 95
- 91
REG - GSK PLC - DREAMM-3 phase III trial for Blenrep
AnnouncementREG - GlaxoSK Capital PLC GSK PLC - Publication of Suppl.Prospcts
AnnouncementREG - Allianz Glbl Inv - Top 10 Holdings
AnnouncementREG - GSK PLC - IDMC recommends gepotidacin early efficacy stop
AnnouncementREG - GSK PLC - 3rd Quarter Results
AnnouncementREG - GSK PLC - GSK RSV vaccine: US FDA Priority Review
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - EMA validates MAA for cabotegravir LA for PrEP
AnnouncementREG - GSK PLC - EMA accepts GSK RSV older adult vaccine for review
AnnouncementREG - GSK PLC - GSK announces FDA meeting outcome on daprodustat
AnnouncementREG - GSK PLC - ContRAst phase III programme for otilimab update
AnnouncementREG - GSK PLC - Board Committee Changes
AnnouncementREG - GSK PLC - RSV older adult vaccine submission in Japan
AnnouncementREG - GSK PLC - Menveo new single-vial approved by US FDA
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Efficacy results for GSK’s older adult RSV vaccine
Announcement